Brainomix has announced a US$6.5 million (£4.8 million) extension to its Series C financing, adding to the funding it secured in March 2025 and bringing the total in the round to US$25.4 million (£18.8 million).
With existing operations in the USA and an extensive portfolio of US Food and Drug Administration (FDA)-cleared artificial intelligence (AI) imaging solutions, the additional capital will enable Brainomix to further expand in the US market, advancing deployment of its AI platforms—including Brainomix 360 Stroke and e-Lung—across multiple hospitals. That is according to a recent press release from the company.
The extension round was led by existing investors Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund, and includes participation from new USA-based investor Modi Ventures.
“This investment reflects strong confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care,” said Michalis Papadakis, chief executive officer (CEO) and co-founder of Brainomix. “Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension, we are well-positioned to enhance customer support across the USA and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments.”
“Brainomix has built an exceptionally strong platform backed by rigorous clinical validation and real-world evidence showing that Brainomix 360 Stroke can significantly increase endovascular thrombectomy treatment rates, and reduce delays in patient triage and transfer, particularly in primary stroke centres. With e-Lung, Brainomix is developing a truly novel technology to accelerate the diagnosis of fibrosing lung disease, enabling earlier treatment options that can improve patient outcomes,” added Sahir Ali, founder and general partner of Modi Ventures. “We are pleased to join as a new investor, and look forward to supporting the company as it expands in the USA and accelerates adoption of technologies that meaningfully improve patient outcomes.”
